Bristol-Myers Squibb
This article was originally published in The Gray Sheet
Executive Summary
Senior VP-Strategy & Organizational Effectiveness Peter Dolan is named president and a member of the board of directors, positioning him as a likely heir to current Chairman and CEO Charles Heimbold. Dolan is credited with building value in each of the company's major business segments, including medical devices. Other key appointments in the senior management team announced Jan. 20 include Senior VP and President-Worldwide Medicines Group Donald Hayden to executive VP responsible for implementing an e-business strategy and managing strategic planning. In addition, President-U.S. Medicines Richard Lane is appointed president-worldwide medicines group, reporting to Dolan. Peter Ringrose becomes chief scientific officer, reporting to Lane. Ringrose continues as president of the Pharmaceutical Research Institute